Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Monday's Featured Story
The Often-Missed Corner of Healthcare That Wall Street Is LovingSubmitted by Nathan Reiff. Posted: 3/29/2026. 
Key Points
- Numerous lab equipment stocks are down in the high-teens so far this year, but seemingly modest sales growth may hide fundamental strengths.
- These companies can present a more secure approach to the healthcare industry than some higher-risk alternatives.
- Still, headwinds including tariff impacts and inflation remain a concern.
- Special Report: Have $500? Invest in Elon’s AI Masterplan
The healthcare industry is notoriously volatile—company fortunes can be made or broken on the success of a single product or the results of a clinical trial—and it's not uncommon for stocks in this sector to produce some of the market's wildest spikes and drops. Investors who want exposure to the healthcare space but are wary of that turbulence may prefer a "picks and shovels" approach, focusing on companies that supply essential equipment and services rather than on higher-risk pharmaceutical names. Lab equipment stocks are often overlooked, even though several companies in this subindustry rank among the largest in healthcare. With a range of external factors potentially affecting healthcare in 2026—shifting subsidies, an aging population, inflation, the growing role of AI, and more—core lab equipment names could become especially attractive. The companies below are among the major players worth a closer look. A Recent Dip Masks Thermo Fisher's Long-Term Strengths
Med-X is gearing up for a possible Nasdaq listing (ticker: MXRX) – and for investors, the biggest potential upside comes before the bell rings.
Med-X is a botanical pesticide company replacing chemical toxins with proven, plant-based solutions. With $6.4M in sales, no long-term debt, and expanding into 41 markets, the company is positioned to capture the surge in global demand for safer pest control.
As the world shifts to sustainable solutions, early investors could benefit from the same type of market recognition that transformed sectors led by innovators like Tesla and Zoom – only this time, in clean pest control.
Simpler. Safer. More Effective Pesticides. Become a Med-X shareholder at $4 per share before the Nasdaq plans unfold...
$182 billion life-sciences, diagnostics, and analytical-instruments company Thermo Fisher Scientific (NYSE: TMO) has had a rough start to 2026, with shares down more than 15% year-to-date (YTD) and the company recently slipping into TradeSmith's red zone for financial health. A sizable part of that weakness appears tied to tariffs and foreign-exchange volatility, which compressed margins by more than 100 basis points in 2025. That said, there are several bright spots in Thermo Fisher's recent performance. In Q4 2025, revenue of $12.2 billion rose 7% year-over-year and beat analyst estimates by about $250 million, while adjusted EPS came in at $6.57, topping forecasts. Momentum may be supported by recent product launches, including the Orbitrap Astral Zoom mass spectrometer and new bioreactor offerings. Thermo Fisher's diversified business model should help it withstand external pressures. Even if 2026 guidance is conservative—revenue is expected to increase roughly 4% to 6%—improving EBITDA margins and steady end-customer demand are encouraging. That may explain why analysts remain largely positive: 17 of 19 rate the stock a Buy or equivalent, and consensus estimates imply more than 29% upside. Danaher's Business May Be Improving, Even as Guidance Remains ModestDanaher Corp. (NYSE: DHR) shares are down nearly 20% YTD, putting the company in a similar situation to Thermo Fisher. Although 2026 guidance points to modest core revenue growth of 3% to 6% year-over-year, the most recent quarter included both a top- and bottom-line beat and generated $5.3 billion in free cash flow for 2025. Two notable growth areas for 2026 are Danaher's bioprocessing segment—expected to deliver high-single-digit revenue gains as demand for monoclonal antibodies remains strong—and its diagnostics business. Diagnostics should benefit from recent FDA clearances, and equipment orders have begun to recover after a prolonged downturn, which could further support sales. Analysts are relatively upbeat on DHR, projecting about 12.3% earnings growth over the coming year and roughly 35% upside in the share price. That optimism is reflected in ratings: 19 of 22 analysts rate DHR a Buy. Agilent's Biocare Purchase Could Be a CatalystAgilent Technologies (NYSE: A) lags some peers after reporting tepid 4.4% year-over-year revenue growth and small misses on both earnings and revenue versus expectations in its latest results. However, Agilent may have a potential growth catalyst in its recent acquisition of Biocare Medical, which strengthens its position in cancer diagnostics. Although the deal cost nearly $1 billion, Biocare should add recurring revenue in a high-demand area. Cancer diagnostics typically carry higher margins than some of Agilent's existing lines, which could help lift operating margins (Agilent's operating margin was 24.6% in the last quarter). Despite a roughly 17% YTD decline, analysts see about 42% upside for Agilent shares. Wall Street's consensus is a Moderate Buy, with 13 of 16 ratings at Buy or similar. |
